» Articles » PMID: 33854544

Molecular Factors Mediating Neural Cell Plasticity Changes in Dementia Brain Diseases

Overview
Journal Neural Plast
Specialty Neurology
Date 2021 Apr 15
PMID 33854544
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Neural plasticity-the ability to alter a neuronal response to environmental stimuli-is an important factor in learning and memory. Short-term synaptic plasticity and long-term synaptic plasticity, including long-term potentiation and long-term depression, are the most-characterized models of learning and memory at the molecular and cellular level. These processes are often disrupted by neurodegeneration-induced dementias. Alzheimer's disease (AD) accounts for 50% of cases of dementia. Vascular dementia (VaD), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD) constitute much of the remaining cases. While vascular lesions are the principal cause of VaD, neurodegenerative processes have been established as etiological agents of many dementia diseases. Chief among such processes is the deposition of pathological protein aggregates including -amyloid deposition in AD, the formation of neurofibrillary tangles in AD and FTD, and the accumulation of Lewy bodies composed of -synuclein aggregates in DLB and PDD. The main symptoms of dementia are cognitive decline and memory and learning impairment. Nonetheless, accurate diagnoses of neurodegenerative diseases can be difficult due to overlapping clinical symptoms and the diverse locations of cortical lesions. Still, new neuroimaging and molecular biomarkers have improved clinicians' diagnostic capabilities in the context of dementia and may lead to the development of more effective treatments. Both genetic and environmental factors may lead to the aggregation of pathological proteins and altered levels of cytokines, such that can trigger the formation of proinflammatory immunological phenotypes. This cascade of pathological changes provides fertile ground for the development of neural plasticity disorders and dementias. Available pharmacotherapy and disease-modifying therapies currently in clinical trials may modulate synaptic plasticity to mitigate the effects neuropathological changes have on cognitive function, memory, and learning. In this article, we review the neural plasticity changes seen in common neurodegenerative diseases from pathophysiological and clinical points of view and highlight potential molecular targets of disease-modifying therapies.

Citing Articles

Mechanisms of cognitive impairment associated with cerebral infarction.

Yin Q, Yang L Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025; 49(10):1692-1699.

PMID: 40074318 PMC: 11897971. DOI: 10.11817/j.issn.1672-7347.2024.240213.


Expression of Neuronal Nicotinic Acetylcholine Receptor and Early Oxidative DNA Damage in Aging Rat Brain-The Effects of Memantine.

Lewandowska M, Rozycka A, Grzelak T, Kempisty B, Jagodzinski P, Lianeri M Int J Mol Sci. 2025; 26(4).

PMID: 40004097 PMC: 11855568. DOI: 10.3390/ijms26041634.


Alterations of Audiovisual Integration in Alzheimer's Disease.

Liu Y, Wang Z, Wei T, Zhou S, Yin Y, Mi Y Neurosci Bull. 2023; 39(12):1859-1872.

PMID: 37812301 PMC: 10661680. DOI: 10.1007/s12264-023-01125-7.


Editorial: Insights into mechanisms underlying brain impairment in aging, volume II.

Dorszewska J, Ong K, Zabel M, Marchetti C Front Aging Neurosci. 2023; 15:1242271.

PMID: 37496756 PMC: 10368071. DOI: 10.3389/fnagi.2023.1242271.


Editorial: Advances in understanding synaptic function and its dysfunction in neurological disorders.

Mohammad F, Shaikh M, Syed Y, Tissir F Front Mol Neurosci. 2023; 16:1239315.

PMID: 37456528 PMC: 10344352. DOI: 10.3389/fnmol.2023.1239315.


References
1.
Freir D, Nicoll A, Klyubin I, Panico S, Mc Donald J, Risse E . Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites. Nat Commun. 2011; 2:336. PMC: 3156817. DOI: 10.1038/ncomms1341. View

2.
Skaper S, Facci L, Zusso M, Giusti P . Synaptic Plasticity, Dementia and Alzheimer Disease. CNS Neurol Disord Drug Targets. 2017; 16(3):220-233. DOI: 10.2174/1871527316666170113120853. View

3.
Dilger R, Johnson R . Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J Leukoc Biol. 2008; 84(4):932-9. PMC: 2538600. DOI: 10.1189/jlb.0208108. View

4.
Hoffmann A, Ettle B, Bruno A, Kulinich A, Hoffmann A, von Wittgenstein J . Alpha-synuclein activates BV2 microglia dependent on its aggregation state. Biochem Biophys Res Commun. 2016; 479(4):881-886. DOI: 10.1016/j.bbrc.2016.09.109. View

5.
Kaufman S, Sanders D, Thomas T, Ruchinskas A, Vaquer-Alicea J, Sharma A . Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo. Neuron. 2016; 92(4):796-812. PMC: 5392364. DOI: 10.1016/j.neuron.2016.09.055. View